Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002;26(1-3):265-78.
doi: 10.1385/IR:26:1-3:265.

Regulation and chance in the ontogeny of B and T cell antigen receptor repertoires

Affiliations
Review

Regulation and chance in the ontogeny of B and T cell antigen receptor repertoires

Michael Zemlin et al. Immunol Res. 2002.

Abstract

The adaptive immune system has to economically generate a large array of T and B cell antigen receptors (T cell receptors [TCRs], B cell receptors [BCRs]) that eliminate both longstanding and novel antigens from the host while preventing the production of deleterious (e.g., autoreactive) antigen receptors. Our studies focus on the mechanisms that shape the development of these antigen receptor repertoires during human ontogeny. The key to BCR and TCR diversity is the third complementarity determining region (CDR3) of the variable domain, which in the immunoglobulin heavy chain and TCR beta chain, is created by the junction between the variable, diversity, and joining gene segments. The CDR3 diversity is constrained by overrepresentation of gene segments and lack of N regions during the first trimester of gestation and then increases exponentially during ontogeny until it reaches adult levels months after birth. This process parallels, and may contribute to, the stepwise acquisition of the ability to respond to specific antigens. Recent studies indicate that maturation of the CDR3 repertoire is not accelerated by premature exposition to extrauterine antigen and thus appears to follow a strictly developmentally regulated program whose pacemaker(s) is still unknown.

PubMed Disclaimer

References

    1. Vaccine. 1998 Aug-Sep;16(14-15):1383-90 - PubMed
    1. J Immunol. 1997 Mar 1;158(5):2477-89 - PubMed
    1. Science. 1985 Mar 29;227(4694):1597-601 - PubMed
    1. J Exp Med. 1998 Dec 7;188(11):2151-62 - PubMed
    1. J Exp Med. 1993 Jul 1;178(1):331-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources